Publication:
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.

dc.contributor.authorJiménez-Fonseca, Paula
dc.contributor.authorCarmona-Bayonas, Alberto
dc.contributor.authorSánchez Lorenzo, Maria Luisa
dc.contributor.authorPlazas, Javier Gallego
dc.contributor.authorCustodio, Ana
dc.contributor.authorHernández, Raquel
dc.contributor.authorGarrido, Marcelo
dc.contributor.authorGarcía, Teresa
dc.contributor.authorEchavarría, Isabel
dc.contributor.authorCano, Juana María
dc.contributor.authorRodríguez Palomo, Alberto
dc.contributor.authorMangas, Monserrat
dc.contributor.authorMacías Declara, Ismael
dc.contributor.authorRamchandani, Avinash
dc.contributor.authorVisa, Laura
dc.contributor.authorViudez, Antonio
dc.contributor.authorBuxó, Elvira
dc.contributor.authorDíaz-Serrano, Asunción
dc.contributor.authorLópez, Carlos
dc.contributor.authorAzkarate, Aitor
dc.contributor.authorLongo, Federico
dc.contributor.authorCastañón, Eduardo
dc.contributor.authorSánchez Bayona, Rodrigo
dc.contributor.authorPimentel, Paola
dc.contributor.authorLimón, Maria Luisa
dc.contributor.authorCerdá, Paula
dc.contributor.authorÁlvarez Llosa, Renata
dc.contributor.authorSerrano, Raquel
dc.contributor.authorLobera, Maria Pilar Felices
dc.contributor.authorAlsina, María
dc.contributor.authorHurtado Nuño, Alicia
dc.contributor.authorGómez-Martin, Carlos
dc.date.accessioned2023-01-25T08:36:17Z
dc.date.available2023-01-25T08:36:17Z
dc.date.issued2016-09-06
dc.description.abstractTrastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national registry of AGC. This Spanish National Cancer Registry includes cases who were consecutively recruited at 28 centers from January 2008 to January 2016. The effect of missing HER2 status was assessed using stratified Cox proportional hazards (PH) regression. The rate of HER2 testing increased steadily over time, from 58.3 % in 2008 to 92.9 % in 2016. HER2 was positive in 194 tumors (21.3 %). In the stratified Cox PH regression, each 1 % increase in patients who were not tested for HER2 at the institutions was associated with an approximately 0.3 % increase in the risk of death: hazard ratio, 1.0035 (CI 95 %, 1.001-1.005), P = 0.0019. Median OS was significantly lower at institutions with the highest proportions of patients who were not tested for HER2. Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.
dc.identifier.doi10.1007/s10120-016-0639-8
dc.identifier.essn1436-3305
dc.identifier.pmid27599830
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s10120-016-0639-8.pdf
dc.identifier.urihttp://hdl.handle.net/10668/10422
dc.issue.number3
dc.journal.titleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
dc.journal.titleabbreviationGastric Cancer
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number465-474
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.rights.accessRightsopen access
dc.subjectGastric cancer
dc.subjectHER2 testing
dc.subjectPersonalized medicine
dc.subjectQuality of care
dc.subjectTrastuzumab
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBiomarkers, Tumor
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrognosis
dc.subject.meshProportional Hazards Models
dc.subject.meshReceptor, ErbB-2
dc.subject.meshSpain
dc.subject.meshStomach Neoplasms
dc.subject.meshTrastuzumab
dc.titlePrognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number20
dspace.entity.typePublication

Files